Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 4 drugs approved in the U.S. (marked with * below). Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.

Oncology
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
Ovarian Cancer (2nd line maintenance) *
Mainland China, HK & Macau (China)
Ovarian Cancer (1st line maintenance)*
Mainland China
Ovarian Cancer (late line treatment)*
Gastric Cancer (combo with tebotelimab)[1, 12]
Other solid tumors[2] (I/O[3] combo)
Glioblastoma (GBM) *
Hong Kong (China), mainland China
Mesothelioma* (Optune Lua)
NSCLC[4]
Brain Metastases
Pancreatic Cancer
Ovarian Cancer
Gastric Cancer[1]
Liver Cancer
GIST[5] (4th Line)*
GIST[5] (2nd Line)
Systemic mastocytosis, etc.
B-NHL - r/r FL, r/r DLBCL, r/r MCL, r/r MZL, etc. [6, 7]
ROS1+ NSCLC[4], NTRK+[8] solid tumors
HER2+ Breast Cancer
HER2+ Gastric/GEJ Cancer[9] (combo studies[10])
Hepatocellular carcinoma (HCC) (combo with brivanib)
Melanoma[1]
Basket trial
NSCLC[11]
MSI-high Endometrial[7]
Gastric/GEJ Cancer[9]
Multiple tumor types
Oncology
Oncology
Oncology and autoimmune disease
No data!
No data!
Infectious Disease and Autoimmune
Molecule Name
Potential Indication
Phase
Pre-clinical
Phase I
Phase II / POC
Phase III / Pivotal
NDA Filed
Marketed
No data!
No data!
No data!
No data!
No data!
Acute Bacterial Skin and Skin Structure Infection (ABSSSI) *
Community-Acquired Bacterial Pneumonia (CABP) *
A.Baumanii Bacterial Infections
Psoriasis, etc.

Note: [1]  China-only trials;  [2] Including non-small cell lung cancer; [3] Immuno-oncology; [4] Non-small cell lung cancer; [5] Gastrointestinal stromal tumors; [6] B-NHL, B-cell non-Hodgkin lymphoma; r/r, relapsed or refractory; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; [7] Potentially registration-enabling trial; [8] Neurotrophic tropomyosin receptor kinase; [9] Gastroesophageal junction cancer; [10] Phase 2/3 study and registration path in first-line gastric & GEJ cancer; combo with retifanlimab and tebotelimab, respectively; [11] Non-small cell lung cancer; Phase 3 in preparation; [12] Bridging study ongoing.